Skip to main content

Table 5 Treatment and outcomes of EGPA patients with and without CNS involvement

From: Clinical features of central nervous system involvement in patients with eosinophilic granulomatosis with polyangiitis: a retrospective cohort study in China

 

With CNS involvement (n = 19)

Without CNS involvement (n = 91)

P value

Treatment, n (%)

   

 GCs

19 (100)

88 (96.7)

1.000

  MP pulse

9 (47.4)

22 (24.2)

0.041*

  CYC

18 (94.7)

80 (87.9)

0.688

  Rituximab

0 (0)

1 (1.1)

1.000

  Plasma exchange

1 (5.3)

0 (0)

0.173

  IVIG

3 (15.8)

11 (12.1)

0.706

Outcomes, n (%)

   

 Complete remission

17 (89.5)

73 (80.2)

0.517

 Partial relief

0 (0)

12 (13.2)

0.122

 Death

2 (10.5)

6 (6.6)

0.625

  1. The categorical variables are expressed as frequencies and ratios, and are further compared by Chi-square analysis or Fisher’s exact test
  2. EGPA, Eosinophilic Granulomatosis with Polyangiitis; CNS, Central Nervous System; GCs, glucocorticoids (including pulse, high, medium, and low doses); MP, methylprednisolone; CYC, cyclophosphamide (including all kinds of doses); IVIG, Intravenous immunoglobulin; *P< 0.05
Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172